Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11801563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.

  2002cited by this paper
• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.

  2002cited by this paper
• Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.

  2001cited by this paper
• Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

  2001cited by this paper
• Redefining the target: chemotherapeutics as antiangiogenics.

  2001cited by this paper
• Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.

  2001cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000influential reference
• Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin

  2000cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000influential reference
• High-time chemotherapy or high time for low dose.

  2000cited by this paper
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

  2000cited by this paper
• Cancer: looking outside the genome

  2000cited by this paper
• Endothelial cell survival and apoptosis in the tumor vasculature

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Role of 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI 571

  2000cited by this paper
• Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

  2000cited by this paper
• Oral cancer chemotherapy: the promise and the pitfalls.

  1999cited by this paper
• Modulation of multidrug resistance: a paradigm for translational clinical research.

  1999cited by this paper
• Treatment of non-small-cell lung cancer with prolonged oral etoposide.

  1998cited by this paper
• Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

  1998cited by this paper
• Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

  1998cited by this paper
• Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

  1998cited by this paper
• The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833.

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.

  1996cited by this paper
• Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

  1995cited by this paper
• Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice.

  1993cited by this paper
• Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.

  1993cited by this paper
• Chemotherapy of mammary carcinomas arising in ras transgenic mice

  1993cited by this paper
• Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5‐fluorouracil

  1992cited by this paper
• Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

  1991cited by this paper
• The biochemistry of P-glycoprotein-mediated multidrug resistance.

  1989cited by this paper
• Cell and environment interactions in tumor microregions: the multicell spheroid model.

  1988cited by this paper
• Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells.

  1988cited by this paper
• Reversible inhibition of mammary gland growth by transforming growth factor-beta.

  1987cited by this paper
• Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus

  1985cited by this paper

• Metronomic Chemotherapy: An Alternative Strategy in Cancer Treatment Based on Continuous Low-Dose Administration

  2025cites this paper
• Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies.

  2025cites this paper
• Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

  2023cites this paper
• All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma

  2023cites this paper
• Resistance to antiangiogenic treatments: A review

  2022cites this paper
• Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer.

  2022cites this paper
• Design, Synthesis and Cytotoxicity Screening of New Thiazole Derivatives as Potential Anticancer Agents through VEGFR-2 Inhibition

  2022cites this paper
• Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data

  2022cites this paper
• Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

  2022cites this paper
• All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma

  2022cites this paper
• Metronomic Therapy in Oral Squamous Cell Carcinoma

  2021cites this paper
• Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?

  2021cites this paper
• 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity

  2021cites this paper
• Low-toxicity FePt nanoparticles for the targeted and enhanced diagnosis of breast tumors using few centimeters deep whole-body photoacoustic imaging

  2020cites this paper
• MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

  2020cites this paper
• Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

  2020cites this paper
• Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate

  2020cites this paper
• Achievements and challenges in the use of metronomics for the treatment of breast cancer.

  2020cites this paper
• Nanoparticles‐Mediated Combination Therapies for Cancer Treatment

  2019cites this paper
• Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

  2019cites this paper
• Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle.

  2019cites this paper
• Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

  2019cites this paper
• Molecular/Targeted Therapy of Cancer

  2019cites this paper
• Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer

  2018cites this paper
• Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

  2018cites this paper
• Studies on Biological Characteristics of Cancer Cells after Acquiring Resistance to Molecular-Targeted Therapy

  2018cites this paper
• Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

  2018cites this paper
• Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells

  2018cites this paper
• Efficacy Study of Metronomic Chemotherapy in Metastatic Triple Negative Breast Cancer and Correlation with VEGF, TSP Levels

  2018cites this paper
• Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.

  2017cites this paper
• The Chemotherapeutic Effect of Docetaxel, Cisplatin and Fluorouracil Regimen on Gastric Cancer Stem Cells.

  2017cites this paper
• Spatial competition constrains resistance to targeted cancer therapy

  2017cites this paper
• Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF‐targeting RNAi nanoparticles

  2017cites this paper
• Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

  2017cites this paper
• Immunomodulatory Activity of VEGF in Cancer.

  2017cites this paper
• Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

  2017cites this paper
• Metronomic chemotherapy and immunotherapy in cancer treatment.

  2017cites this paper
• Oncolytic viruses: emerging options for the treatment of breast cancer

  2017cites this paper
• Nanoformulations for combination or cascade anticancer therapy.

  2017cites this paper
• Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts

  2017cites this paper
• EFFICACY STUDY OF METRONOMIC CHEMOTHERAPY IN METASTATIC NSCLC AND CORRELATION WITH VEGF AND THROMBOSPONDIN LEVELS

  2017cites this paper
• Natural products against cancer angiogenesis

  2016cites this paper
• Meta-analysis of the association between appendiceal orifice inflammation and appendectomy and ulcerative colitis.

  2016cites this paper
• Eco-evolution of cancer resistance

  2016cites this paper
• Future paradigms for precision oncology

  2016influential citation
• Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow

  2016cites this paper
• Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

  2016cites this paper
• Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• Bayesian Accelerated Failure Time and its Application in Chemotherapy Drug Treatment Trial

  2016cites this paper
• Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

  2016cites this paper
• Generation and characterization of a human nanobody against VEGFR-2

  2016cites this paper
• A Model for Spheroid versus Monolayer Response of SK-N-SH Neuroblastoma Cells to Treatment with 15-Deoxy-PGJ 2

  2016cites this paper
• Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

  2016cites this paper
• Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.

  2016cites this paper
• The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth

  2016cites this paper
• Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort

  2015cites this paper
• K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2.

  2015cites this paper
• Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis

  2015cites this paper
• Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing

  2015cites this paper
• Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein.

  2015cites this paper
• Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.

  2015cites this paper
• The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics.

  2015cites this paper
• The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

  2015cites this paper
• Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1,3,4-oxadiazole scaffold as novel inhibitors of VEGFR2

  2015cites this paper
• Bioinformatic analysis of potential candidates for therapy of inflammatory bowel disease.

  2015cites this paper
• Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.

  2014cites this paper
• The role of the proline rich homeodomain in the regulation of proliferation, survival and migration of breast cells

  2014cites this paper
• Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective

  2014cites this paper
• Metronomic Chemotherapy : Possible Clinical Application in Advanced Hepatocellular Carcinoma 1

  2014cites this paper
• Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice

  2014cites this paper
• Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments

  2014cites this paper
• Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin

  2013cites this paper
• Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

  2013cites this paper
• Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

  2013cites this paper
• Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.

  2013cites this paper
• UNIVERSIDADE ESTADUAL PAULISTA “JÚLIO DE MESQUITA FILHO” UNESP INSTITUTO DE BIOCIÊNCIAS – CAMPUS DE BOTUCATU DEPARTAMENTO DE MICROBIOLOGIA E IMUNOLOGIA REVIEW IMMUNOMODULATORY EFFECTS OF LOW DOSE CHEMOTHERAPY AND PERSPECTIVES OF COMBINATION WITH IMMUNOTHERAPY ALUNA: MARIANA DE SOUZA NARS ORIENTADO

  2013cites this paper
• Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature

  2013cites this paper
• Rational development and utilization of antibody-based therapeutic proteins in pediatrics.

  2013cites this paper
• Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.

  2013cites this paper
• Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

  2013cites this paper
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

  2013cites this paper
• Angiogenesis in Brain Tumors

  2013cites this paper
• A tissue-engineered gastric cancer model for mechanistic study of anti-tumor drugs

  2013cites this paper
• Primary peritoneal low-grade serous carcinoma forming a mass in the colon mimicking a colonic primary carcinoma: a case report.

  2013cites this paper
• Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice.

  2013cites this paper
• Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.

  2013cites this paper
• Impact of Chemotherapy Dosing Schedule on Ovarian Cancer Tumor Responsiveness

  2012cites this paper
• Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors

  2012cites this paper
• Targeting Angiogenesis in Advanced Breast Cancer

  2012cites this paper
• Inhibiting angiogenesis in malignant gliomas.

  2012cites this paper
• Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

  2012cites this paper
• A Guide to Rational Dosing of Monoclonal Antibodies

  2012cites this paper
• Targeted therapy in ovarian cancer : novel agents and predictive biomarkers

  2011cites this paper
• Towards Tailored Therapy of Glioblastoma Multiforme

  2011cites this paper
• Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft

  2011cites this paper
• Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.

  2011cites this paper
• Metronomic dosing enhances the anti-angiogenic effect of epothilone B.

  2011cites this paper
• The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

  2011cites this paper
• "Targeted Therapy in ovarian cancer: novel agents and predictive biomarkers"

  2011cites this paper